Skip to main content
  • ENG
  • FR

Search form

Medicines for Malaria Venture

Developing antimalarials to save lives

  • Research & Development
    • MMV-supported projects
    • R&D areas of work
      • Next-generation medicines
      • Science of eradication
      • Products for vulnerable populations
    • Working with regulators
    • Information for scientists
      • Call for proposals
      • TPPs & TCPs
    • Project of the year award
    • Computational chemistry
      • Global health compound design webinars
    • R&D challenges
  • Access
    • Products & projects
    • Areas of work
      • Supporting introduction
      • Enhancing reach
      • Informing R&D
      • Gathering market intelligence
    • Product maps
      • ASAQ Winthrop® map
      • ASMQ map
      • Artesun® map
      • Coartem® Dispersible map
      • Eurartesim® map
      • Kozenis/Krintafel map
      • Pyramax® map
      • Pyramax® granules map
      • Rectal artesunate map
      • SPAQ map
    • Tool Kits
      • Injectable artesunate tool kit
      • Rectal artesunate tool kit
      • Seasonal Malaria Chemoprevention Tool Kit
    • The road to health impact
    • Access challenges
  • Partnering
    • Our partner network
    • The PDP model
    • Socially responsible agreements
    • Our clinical centre partners
    • Our donors
      • Current donors
      • Past donors
      • Donate to MMV
      • Donor stories
  • Our impact
    • Achievements
    • Real life stories
    • Impact of the global malaria community
  • About us
    • What we do
      • An overview of our work
      • Our strategic focus
      • Our history
    • People & governance
      • Staff bios
      • Staff map
      • Staff interviews
      • Board of Directors
      • MMV North America Board
      • Expert Scientific Advisory Committee
      • Access & Product Management Advisory Committee
      • Global Safety Board
    • Work with us
      • Jobs
      • RFPs/RFIs
      • MMV's internship programme
    • Policies
    • Funding and expenditure
    • FAQs
    • Contact us
  • Malaria & medicines
    • Definitions and symptoms
    • Five species
    • Parasite lifecycle
    • Malaria facts & figures
    • Malaria treatment
    • History of antimalarials
    • Optimizing artemisinin production
    • Malaria online course
  • Newsroom
    • News & Press Releases
    • Films
    • Infographics
    • Interviews
    • Image slideshows
    • Publications
    • Audio
    • Events
  • MMV Open
    • Pandemic Response Box
      • About the Pandemic Response Box
      • Request the Pandemic Response Box
      • Supporting information
      • Terms & conditions
    • Pathogen Box
      • About the Pathogen Box
      • Request the Pathogen Box
      • Exploiting the Pathogen Box
      • Pathogen Box research
      • Supporting information
      • Terms & conditions
    • Malaria Box
      • About the Malaria Box
      • Malaria Box Research
      • Supporting information
      • Terms & conditions
    • Map of box orders
    • Follow-up guidelines
    • Open Source Drug Discovery
    • MMV Open Team
    • Contact us
  • Igniting drug discovery for pandemic preparedness

  • Our 17th Call for proposals in now open!

    Photo: Eskitis Institute, Griffith University Photo: Eskitis Institute, Griffith University
  • US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria

    Photo: Vivian Zanatta

Achievements

  • .
    USD 1
    = USD 3.5

    of investment impact thanks to direct and in-kind support from partners

  • .
    Single-dose
    tafenoquine

    for relapse prevention of P. vivax malaria approved by the US FDA

  • .
    >90%
    of severe malaria cases

    now treated with injectable artesunate in preference to quinine across 6 countries through the MMV-led ISMO project

Home

News

Pandemic Response Box harnesses open and collaborative approaches to medical innovation

MMV and DNDi make 400 compounds available to stimulate research into new drugs for pandemic diseases

29 Jan 2019
Press release

Two positive phase III studies of tafenoquine for the radical cure of Plasmodium vivax malaria published in The New England Journal of Medicine

16 Jan 2019
Press release

MMV Board Member recognized for services to science

Professor Michael Ferguson receives Knighthood in New Year’s Honours List

14 Jan 2019
News story

A message from MMV's CEO, David Reddy

2018 - A triumph of partnerships

19 Dec 2018
News story
View all news

Defeating malaria together

  • Real life stories

  • Annual Report 2017

  • Open source research

Featured resources

  • Why we must prioritize malaria treatment for children

    Jan 2019
    Article
  • Evaluation of the effects on the QT interval of 4 artemisinin-based combination therapies for the treatment of uncomplicated malaria by use of a correction-free and heart rate-free method

    Jan 2019
    Scientific article
  • Effects of Dihydroartemisinin-Piperaquine Phosphate and Artemether-Lumefantrine on QTc Interval Prolongation

    Jan 2019
    Scientific article

Events

  • 20
    Feb

    7th International Symposium on Current Trends in Drug Discovery Research

    20-23 February 2019
    Lucknow, India
  • 07
    Mar

    9th Annual Pharma PPM Toolbox

    7-8 March 2019
    Basel, Switzerland
  • 24
    Apr

    GSK Tres Cantos World Malaria Day

    24 April 2019
    Tres Cantos, Madrid, Spain
View all events
  • RSS subscribe
    Printer friendly

Follow us

  • Facebook
  • LinkedIn
  • Twitter
  • GooglePlus
  • YouTube

Subscribe

Previous newsletters

Contact us

  • Tel: +41 22 555 03 00
    • Message us
    • Office directions
© MMV 2019
Website by Manta Ray Media
  • Glossary
  • Disclaimer
  • Privacy
  • Sitemap